Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
出版年份 2014 全文链接
标题
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 111, Issue 9, Pages 1750-1756
出版商
Springer Nature
发表日期
2014-10-01
DOI
10.1038/bjc.2014.519
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
- (2014) Helmout Modjtahedi et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
- (2013) Diana P. English et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
- (2013) Roger B. Cohen CANCER TREATMENT REVIEWS
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
- (2013) Y. Y. Janjigian et al. JOURNAL OF NUCLEAR MEDICINE
- Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
- (2013) Natalia Buza et al. MODERN PATHOLOGY
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
- (2013) S. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling
- (2012) Z Hartman et al. ONCOGENE
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
- (2010) T. Hickish et al. CANCER RESEARCH
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- (2009) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started